Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China

Colorectal Cancer Clinical Trial

— SCI-101  

Official title:

A Multicenter Feasibility Study With S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients With Untreated Metastatic Colorectal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01110941
• Other study ID #: SOL feasibility study
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: April 21, 2010
• Last updated: May 17, 2015
• Start date: September 2009
• Est. completion date: October 2010

Study information

• Verified date: May 2015
• Source: Peking University
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug AdministrationChina: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

S-1 is an oral fluoropyrimidine with demonstrated efficacy on gastric cancer and colorectal cancer. The new regimen with Oxaliplatin and leucovorin is expected to achieve more encouraging efficacy on colorectal cancer. This study is to explore the feasibility of the SOL regimen on efficacy and tolerability on Chinese colorectal cancer patients.

Description:

• Endpoints:

• Primary endpoints: adverse drug reaction

• Secondary endpoints:

• Overall Response Rate：ORR

• Progress Free Survival: PFS

• Time to Treatment Failure：TTF

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: October 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

• Advanced unresectable or recurrent colorectal cancer patients which meet the following criteria:

• Willing to sign ICF

• Could orally take investigational product

• Pathology diagnosis is adenocarcinoma

• Above 20 years

• No previous treatment(including: radiotherapy,chemotherapy and immunotherapy)

• For recurrent cases, if the patient had received adjuvant chemotherapy that didn't include S-1 and L-OHP in 180 days ago, he/she could be enrolled in

• With target lesions with diameter which is longer than 1cm in spiral CT or MRI examination within 30 days

• Lab test within 15 days meet following criteria

• Hemoglobin higher than 9.0g/dL

• Leukocyte higher than 12,000/mm3

• Neutrophil higher than 2,000/mm3

• PLT higher than 10.0 104/mm3

• Bilirubin lower than 1.5 times of upper limit of normal range

• AST,ALT,ALP lower than 2.5 times of upper limit of normal range

• Creatinine lower than upper limit of normal range

When patient has liver metastasis or bone metastasis, the value of AST,ALT,ALP could be within 5 times of upper limit of normal range

• ECOG 0 or 1

• Expected survival time more than 90 days

Exclusion Criteria:

• The patient who meet the following criteria should be excluded from this trial

• Patients who have severe drug allergic history(including: platinum related drugs,5-FU,FT,LV,5-HT3 receptor antagonist)

• Attended other clinical trial within 4 weeks

• Received transfusion of blood,related products or G-CSF within 15 days

• Received surgery within 4 weeks and the effect hadn't vanished

• Have diarrhea

• Have complication of active infection(infection caused fever higher than 38?)

• Have complication of poor controlled hypercalcemia,hypertension,diabetes

• Have complication of severe ECG abnormal or other heart disease which will affect clinical treatment(including: cardiac dysfunction,myocardial infarction,angina)

• Have complication of severe pulmonary disease(including:interstitial pneumonia,pulmonary fibrosis,severe emphysema)

• Have complication of psychiatric disorder which will affect clinical treatment or have history of CNS disease

• Have complication of active gastrointestinal bleeding

• Have pleural effusion,ascites or pericardial effusion that need drainage

• Have complication of multiple bone metastasis

• Have severe complication(including:ileus,renal insufficiency,hepatic insufficiency,cerebrovascular disturbance)

• Have brain metastasis or suspicious brain metastasis

• Have active multiple primary cancer

• Female patients who are in pregnancy or lactation and patients who are not willing to take contraception measures

• Investigator judge not eligible to this trial

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Drug:
• S-1, leucovorin, oxaliplatin
S-1(20mg?25mg), capsule, 40~60mg, Bid,p.o., day1~7; LV (25 mg), tablet, 25mg,Bid,p.o., day1~7; L-OHP (50 mg),injection 85mg/m2, day1. repeated at every 2 weeks cycle till disease progression.

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing	Beijing

Sponsors (5)

Lead Sponsor	Collaborator
Shen Lin	307 Hospital of PLA, Beijing Union Hosptial, Hebei Provincial Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with Adverse Events as a Measure of Safety and Tolerability		from first administration till 28 days after last dosage	Yes
Secondary	Tumor response according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, and follow up till disease progression or withdrawal from study due to intolerable adverse events (AE)		every 6 weeks	No